ORPHELIA Pharma is a pharmaceutical company aiming at developing and marketing paediatric drugs in oncology, CNS and metabolic diseases.
Our mission is to provide meaningful advances to children through the development of efficient, reliable and easy-to-use medicines.
Latest news and reports
Discover our pipeline
ORP-001
ORP-001 is a reformulation of the antiepileptic
drug vigabatrin which makes its administration to young
patients easier and safer too. ORP-001 clinical evaluation
is completed and MA dossier is currently under EMA
review.
Click to visit
ORP-005
ORP-005 is a paediatric formulation of an essential medicine used to treat CNS tumors. ORP-005 is currently under clinical development.
Click to visit
ORP-008
ORP-008 is a drug targeting childhood neuroblastoma with a novel mechanism of action. ORP-008 is currently under preclinical development in this orphan indication.
Click to visit
ORP-009
ORP-009 is a drug that targets various CNS cancers by repositioning a known medicine.
Click to visit
